These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 299828)

  • 21. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
    Nakamura T
    Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of overall toxicity of high-dosage methotrexate regimens.
    Perez C; Sutow WW; Wang YM; Herson J
    Med Pediatr Oncol; 1979; 6(3):219-28. PubMed ID: 314042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteosarcoma--the winds of change.
    Mills EE
    S Afr Med J; 1978 May; 53(18):695-8. PubMed ID: 308700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
    Allen JC; Rosen G
    Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor).
    Juergens H; Kosloff C; Nirenberg A; Mehta BM; Huvos AG; Rosen G
    Natl Cancer Inst Monogr; 1981 Apr; (56):221-6. PubMed ID: 6975439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic aspects of chemotherapy response in the treatment of osteogenic sarcoma. An analysis of two cases.
    Marroum MC; Huvos AG; Rosen G
    Oncology; 1977; 34(6):273-80. PubMed ID: 304199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
    Jaffe N; Frei E; Watts H; Traggis D
    Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
    [No Abstract]   [Full Text] [Related]  

  • 30. Vincristine in the etiology of toxicity of high-dose methotrexate therapy.
    Ridgway D; Renholds DC; Neerhout RC; Wolff LJ
    Cancer; 1980 Dec; 46(12):2571-2. PubMed ID: 6969624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma.
    Rosen G; Murphy ML; Huvos AG; Gutierrez M; Marcove RC
    Cancer; 1976 Jan; 37(1):1-11. PubMed ID: 1082364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
    Pongracz N; Kelaridis T; Ritschl P
    Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas.
    Baumgartner G; Heinz R; Arbes H; Lenzhofer R; Pridun N; Schüller J
    Cancer Treat Rep; 1980 Jan; 64(1):41-6. PubMed ID: 6155211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
    Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
    Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma.
    Shamberger RC; Rosenberg SA; Seipp CA; Sherins RJ
    Cancer Treat Rep; 1981; 65(9-10):739-46. PubMed ID: 6791818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [High-dose methotrexate with citrovorum factor rescue (HD-MTX-CFR) in the treatment of malignant solid tumors--clinical analysis of 62 patients].
    Wang QL; Sun Y; Zhou JC; Song SZ; Feng FY; Lu L; Yie ZS
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):152-4. PubMed ID: 3264785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical observations on the use of high-dose methotrexate treatment in osteogenic sarcoma (author's transl)].
    Kotz R; Leber H; Ramach W; Arbes H; Wolf A
    Wien Klin Wochenschr; 1977 Jul; 89(14):474-9. PubMed ID: 70889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The results of using high-dose methotrexate in treating osteogenic sarcoma].
    Perevodchikova NI; Eremina LA; Manziuk LV; Siniukov PA; Fedenko AN; Singin AS; Moldovanova LK
    Vopr Onkol; 1990; 36(6):667-71. PubMed ID: 2378085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.